Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Genomics identified as the most impactful emerging pharmaceutical industry trend for 2023, according to GlobalData survey

Genomics will continue to play a significant role in helping to understand, prevent, and treat diseases throughout 2023. Coupled with continuous advancements in sequencing and data analyzing technologies, genomics holds the potential to enhance the speed of diagnosis and provide opportunities to personalize patient treatment approaches, says GlobalData, a leading data and analytics company. A survey […]
Read more

Inflation, drug pricing and reimbursement constraints will have the biggest negative impact on biopharmaceutical industry in 2023, finds GlobalData

The biopharmaceutical industry has long been labelled as recession-proof, with stable demand for medicines and new treatment options acting as a protective barrier. Nevertheless, inflation, coupled with drug pricing and reimbursement constraints, will put high pressure on the biopharmaceutical industry’s growth prospects in 2023, says GlobalData, a leading data and analytics company. A survey by GlobalData*, […]
Read more

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData

China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM). As a result, the number of clinical trials conducted in the country for this indication is gradually increasing, driven mostly by international pharmaceutical companies, but lacks substantial […]
Read more

Promising Phase I data sets latecomer Amgen’s AMG-133 on a trajectory to compete with Novo Nordisk and Eli Lilly in obesity space, says GlobalData

Amgen’s AMG-133* has the potential to address a key unmet need for drugs that reduce patient burden among patients with obesity, says GlobalData, a leading data and analytics company. Sara Reci, Pharma Analyst at GlobalData, comments: “Currently, patients receiving pharmacotherapy for obesity, such as glucagon-like peptide-1 receptor (GLP-1R), are required to self administer Wegovy (semaglutide) […]
Read more

Congenital fibrinogen deficiency market will surpass $800 million across the 3MM by 2031, driven by demand for plasma-derived therapies, says GlobalData

The congenital fibrinogen deficiency (CFD) market is forecast to increase from $673 million in 2021 to over $800 million in 2031 at a compound annual growth rate (CAGR) of 1.7% across the three major markets (3MM*). Growth will be driven by the launch of improved human fibrinogen concentrate (HFC) products, the large market potential for HFC […]
Read more

Bispecific antibodies will threaten cell therapy in multiple myeloma in 2023, says GlobalData

A relatively novel class of drugs called bispecific T-cell engagers (BiTEs) present a serious threat to the market position of Bristol Myers-Squibb’s Abecma (ide-cel) for the treatment of relapsed or refractory multiple myeloma (RRMM) as they leverage clinical advantages such as improved duration of response to therapy and quicker administration, says GlobalData, a leading data […]
Read more

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

The current diabetic neuropathic pain treatment paradigm includes many established analgesics that provide symptomatic relief. However, as these therapies do not target the pathophysiological mechanisms underlying the pain, they typically only work in a subset of patients, and provide only partial pain relief. Furthermore, the established marketed analgesics have been associated with poor safety profiles. […]
Read more

Historically unimpressive field of therapeutic cancer vaccines gets revitalized with Moderna and Merck mRNA data, says GlobalData

Historically, therapeutic cancer vaccines have demonstrated minimal efficacy. However, for the first time, an anti-cancer vaccine has shown significant promise in a clinical trial. The combination therapy of Moderna’s mRNA vaccine “mRNA-4157/V940” in combination with Merck & Co’s anti-PD-1 therapy “Keytruda”  has reportedly cut the risk of melanoma recurrence or death by 44% compared to […]
Read more

Strong uptake expected for AbbVie’s Vraylar in major depressive disorder market, says GlobalData

Following the news that AbbVie’s Vraylar (cariprazine) gained approval from the FDA for the adjunctive treatment of major depressive disorder (MDD) in adults; Pippa Salter, Senior Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “In the MDD market, there is a need for therapies that can treat patients who are inadequately responding […]
Read more

Dupixent’s safety concerns unlikely to impact prescriptions, says GlobalData

Recently, the UK’s Medicines, and Healthcare Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Sanofi & Regeneron’s Dupixent, a drug used in the treatment of numerous allergic indications. Leading data and analytics company, GlobalData, notes that, although this safety update will likely raise physician vigilance regarding long-term Dupixent […]
Read more

CanSino Biologics inhaled vaccine Convidecia Air to gain good momentum amid plans to boost elderly vaccination in China, says GlobalData

In a clear shift away from its long-held stringent zero-COVID policy, China has recently relaxed rules that contained the spread of the virus but impacted the world’s second largest economy. Subsequently, the National Health Commission (NHC) pledged to step up vaccination among the elderly. Against this backdrop, considering that CanSino Biologics’ inhaled vaccine Convidecia Air […]
Read more

50% of healthcare industry professionals would prioritize investing in AI in the next two years, finds GlobalData survey

According to a survey by GlobalData, 50% of healthcare industry professionals would prioritize artificial intelligence (AI) among other emerging technologies for their investments in the next two years. The leading data and analytics company notes that AI has been trending as the leading future investment target in the pharmaceutical industry since 2018, gaining a 6% […]
Read more
1 … 39 40 41 42 43 … 108